Kinstellar has successfully advised shareholders of the Czech company QUINTA-ANALYTICA, an established provider of R&D and regulatory services for the pharmaceutical, biotechnology and generic drug industries, on the sale of their 75 per cent share in QUINTA-ANALYTICA to Genesis Private Equity Fund III (GPEF III). The transaction represents a first investment for GPEF III, which has approximately EUR 80 million available for investments in small and medium-sized enterprises in the Czech Republic and Slovakia.
QUINTA-ANALYTICA is one of the largest companies in CEE providing commercial services for pharmaceutical companies specialising in analytical services that support the development and manufacture of new medicines. Its services are utilised in the clinical studies and laboratory analyses required by national authorities for drug approval before a new product launch. In 2015, the company achieved revenues of EUR 256 million.
Kinstellar advised the shareholders on all aspects of the transaction, including preparation and negotiation of the transaction documentation, which consisted of a framework agreement, shareholders agreement and management and consultancy agreement.
The Kinstellar team was led by Jan Juroska (Partner) with the support of Michal Kniz and Ivana Frantesova.
